Holen Sie sich die Stockscreener-App
15.50
2.15%
-0.34
Handel nachbörslich:
15.90
0.40
+2.58%
Schlusskurs vom Vortag:
$15.84
Offen:
$15.72
24-Stunden-Volumen:
509.19K
Relative Volume:
0.38
Marktkapitalisierung:
$1.32B
Einnahmen:
$42.95M
Nettoeinkommen (Verlust:
$-130.01M
KGV:
-9.5221
EPS:
-1.6278
Netto-Cashflow:
$-19.66M
1W Leistung:
-2.39%
1M Leistung:
-33.93%
6M Leistung:
-13.50%
1J Leistung:
+256.32%
1-Tages-Spanne:
$15.37
$15.83
1-Wochen-Bereich:
$15.37
$16.27
52-Wochen-Spanne:
$4.30
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Firmenname
Monte Rosa Therapeutics Inc
Sektor
Branche
Telefon
617-949-2643
Adresse
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
15.50 | 1.36B | 42.95M | -130.01M | -19.66M | -1.6278 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Eingeleitet | UBS | Buy |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-10-14 | Eingeleitet | SVB Leerink | Mkt Perform |
Alle ansehen
Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten
Widening Losses And Profitability Swing Might Change The Case For Investing In Monte Rosa Therapeutics (GLUE) - simplywall.st
Monte Rosa Therapeutics (GLUE) holders report sub‑5% stakes in amended 13G - Stock Titan
Monte Rosa Therapeutics (GLUE): Vestal Point discloses 4.6M-share, 5.4% ownership - Stock Titan
GLUE|Monte Rosa Therapeutics Inc|Price:15.500|Chg%:-0.340 - TradingKey
Industry Analysts Just Upgraded Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Revenue Forecasts By 21% - webull.com
Why Monte Rosa Therapeutics (GLUE) Is Back In Focus After Its Latest Update - Sahm
Analysts Are Upgrading Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) After Its Latest Results - webull.com
What Monte Rosa Therapeutics (GLUE)'s Swing From Profit To Deeper Losses Means For Shareholders - simplywall.st
Monte Rosa Therapeutics (NASDAQ:GLUE) Announces Earnings Results - marketbeat.com
MONTE ROSA THERAPEUTICS, INC. : WELLS FARGO CUTS TARGET PRICE TO $27 FROM $29 - webull.com
Monte Rosa Therapeutics, Inc. (GLUE) stock price, news, quote and history - Yahoo Finance Singapore
The Manufacturers Life Insurance Company Raises Stake in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Dimensional Fund Advisors LP Acquires 473,005 Shares of Monte Rosa Therapeutics, Inc. $GLUE - marketbeat.com
JPMorgan Chase & Co. Has Lowered Expectations for Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price - MarketBeat
Wells Fargo & Company Lowers Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target to $27.00 - marketbeat.com
Monte Rosa Therapeutics Is Maintained at Overweight by Wells Fargo - Moomoo
LifeSci Capital Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating - Moomoo
Monte Rosa Therapeutics (GLUE) Is Down 30.7% After Deepening Q2 Losses And H1 Earnings Reversal - Yahoo Finance
Monte Rosa Therapeutics earnings missed by $0.05, revenue fell short of estimates - Investing.com Canada
(GLUE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Monte Rosa Therapeutics, Inc. Stock 12‑Month Price Target Cut to $30.33, Implies 94% Upside - TradingView
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Zacks Research Upgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to "Hold" - MarketBeat
Monte Rosa Therapeutics: Q2 Earnings Snapshot - AOL.com
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D - TradingView
Monte Rosa posts $43.4 million Q2 loss as pipeline trials advance - Quiver Quantitative
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - The Manila Times
Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q2 Collaboration Revenue $9.0M, Vs. FactSet Est of $12.9M - Moomoo
Monte Rosa Therapeutics reports Q2 2026 net loss $43.4M, cash position $626.0M supporting operations into 2029 - TradingView
Monte Rosa Therapeutics Q2 2026: Revenue $9M, EPS $(0.43) — 10-Q Summary - TradingView
Monte Rosa Therapeutics (NASDAQ: GLUE) posts 2026 net loss on revenue drop - Stock Titan
BRIEF-Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million - TradingView
Press Release: Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - Moomoo
GLUE SWOT Analysis: Financial Challenges and Strategic Collabora - GuruFocus
Monte Rosa earnings on deck as cardiovascular data looms By Investing.com - Investing.com India
Monte Rosa Eyes Key Pipeline Readouts; Wedbush Analyst Reiterates Outperform Rating - RTTNews
Janus Henderson Group PLC Invests $11.29 Million in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Renaissance Technologies LLC Makes New Investment in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target Lowered to $27.00 at Wedbush - marketbeat.com
Monte Rosa Therapeutics (GLUE) Plunges 27%: Critical Support Test After Steep SelloffConversion Trade - dars.gov.et
Arrowstreet Capital Limited Partnership Acquires 340,088 Shares of Monte Rosa Therapeutics, Inc. $GLUE - marketbeat.com
Why is Monte Rosa Therapeutics stock plunging today? By Investing.com - Investing.com Canada
Monte Rosa, BioAge plunge as Novo’s setback casts a shadow over pipeline - Seeking Alpha
Monte Rosa Therapeutics (GLUE) to Release Earnings on Thursday - marketbeat.com
Monte Rosa Therapeutics Inc - TradingKey
Analysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), Atea Pharmaceuticals (AVIR) - The Globe and Mail
Exome Asset Management LLC Takes $2.95 Million Position in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics Inc (GLUE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Monte Rosa Therapeutics Inc (GLUE) Cash Flow - TradingKey
Finanzdaten der Monte Rosa Therapeutics Inc-Aktie (GLUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):